As an oral direct inhibitor of factor Xa, Apixaban is approved after dabigatran etexilate and rivaroxaban, which has been used for prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee replacement surgery. This article discusses the discovery, mechanism, pharmacokinetics, and clinical trials of this emerging drug.% 阿哌沙班是口服 Xa 因子直接抑制剂，继达比加群酯和利伐沙班后上市，用于择期髋关节或膝关节置换手术的成年患者，以预防静脉血栓形成。本文主要介绍这个新药的研发背景、作用机制、药动学和临床试验。
展开▼
